Related Experiment Video
Updated: May 9, 2025
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
18.2K
4-Octyl Itaconate Modulates Dendritic Cells Function and Tumor Immunity via NRF2 Activation
Bo Zhu1,2,3, Lihua Zhu2, Zongxia Ge2
1Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University; Institute of Neuroscience and Jiangsu Key Laboratory of Neuropsychiatric Diseases, Soochow University, Suzhou, Jiangsu Province, 215000, People's Republic of China.
Journal of Inflammation Research
|May 5, 2025
Summary
4-octyl itaconate (4OI) represses dendritic cell (DC) maturation and function by activating the KEAP1/NRF2 pathway. This finding is crucial for developing novel DC-based tumor immunotherapy strategies.
Area of Science:
- Immunology
- Cancer Research
- Metabolomics
Background:
- Dendritic cells (DCs) are critical for anti-tumor immunity.
- Factors suppressing DC function can compromise anti-tumor responses.
- Itaconate, an immunomodulatory metabolite, has an unexplored role in DCs.
Purpose of the Study:
- To investigate the role of itaconate in regulating DC maturation and function.
- To elucidate the molecular mechanisms underlying itaconate's effects on DCs.
Main Methods:
- Bone marrow-derived dendritic cells (BMDCs) were treated with 4-octyl itaconate (4OI).
- DC maturation markers (CD40, CD80, CD86, MHC-II) and cytokine expression were analyzed.
- T cell responses were assessed in vitro and in vivo; NRF2 pathway activation was examined.
Main Results:
- 4OI treatment repressed DC maturation and function, indicated by reduced co-stimulatory molecules and pro-inflammatory cytokines.
- 4OI-treated DCs showed diminished capacity to stimulate T cell responses.
- Mechanistically, 4OI inhibited DCs via enhanced activation of the KEAP1/NRF2 pathway.
Conclusions:
- 4-octyl itaconate inhibits DC function through NRF2 activation.
- This study elucidates itaconate's immunomodulatory mechanisms.
- Findings highlight potential for targeted DC-based tumor immunotherapy.
